Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application

GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif., June 24, 2024 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO®…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks